Literature DB >> 31273801

A new strategy for taste masking on bitter drug by other combined drug in fixed-dose combination: bitterness of Amlodipine besylate could be masked efficiently by Valsartan.

Honami Kojima1, Saki Nakamura1, Tamami Haraguchi1, Miyako Yoshida1, Masaaki Habara2, Hidekazu Ikezaki2, Takahiro Uchida1.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the bitterness of amlodipine besylate (AML) combined with other five antihypertensive drugs: alacepril, benazepril, hydrochlorothiazide, telmisartan (TEL) and valsartan (VAL), which have possibility of usage as a fixed-dose combination (FDC) drugs.
METHODS: The bitterness of individual six drugs and AML combined with each of the five drugs was evaluated using taste sensor SA402B (Intelligent Sensor Technology Inc.). AML combined with TEL or VAL was evaluated by taste sensor and human gustatory sensation tests. The interaction between AML with TEL or VAL was evaluated by 1 H-NMR. KEY
FINDINGS: The bitterness of AML was significantly decreased by addition of VAL, whereas it remained unchanged by the addition of TEL in taste sensor and human gustatory sensation test. In the 1 H-NMR spectrum of AML with VAL, signal shifts of protons in AML were observed compared to that in AML alone. On the other hand, in the 1 H-NMR spectrum of AML with TEL, signal shifts of protons in AML were not observed.
CONCLUSIONS: It was suggested that when VAL was mixed with AML, the electrostatic interactions between positive charged amino group of AML and negative charged tetrazole group of VAL were caused, and thereby led the suppression the bitterness of AML.
© 2019 Royal Pharmaceutical Society.

Entities:  

Keywords:  amlodipine besylate; bitterness; fixed-dose combination; taste sensor; valsartan

Mesh:

Substances:

Year:  2019        PMID: 31273801     DOI: 10.1111/jphp.13134

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Study on Masking the Bitterness of Chinese Medicine Decoction-Mate.

Authors:  Fuguo Hou; Yan Miao; Xiangxiang Wu; Xinjing Gui; Yanli Wang; Haiyang Li; Junhan Shi; Lu Zhang; Jing Yao; Xuelin Li; Ruixin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-09       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.